Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

Colon Cancer Clinical Trial

— NeoCHIC  

Official title:

Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06368141
• Other study ID #: 2023294
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: May 1, 2024
• Est. completion date: April 30, 2026

Study information

• Verified date: November 2023
• Source: Ruijin Hospital
• Contact: Tao Zhang, PhD
• Phone: +86 13918805942
• Email: woodyhom[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn the effect of neoadjuvant chemotherapy plus sequential immune checkpoint inhibitor (ICI) therapy in locally advanced colon cancer. The main questions it aims to answer are: - Does this neoadjuvant chemotherapy increase the pathologic complete response (pCR) of locally advanced colon cancer? - Does this neoadjuvant chemotherapy improve the long-term survival of locally advanced colon cancer? Participants will receive: - a pre-operative CAPEOX (capecitabine oral + oxaliplatin i.v.)regimen. - a sequential CAPEOX plus Serplulimab regimen. - a standard complete mesocolic excision (CME) operation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 56
• Est. completion date: April 30, 2026
• Est. primary completion date: February 28, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients who volunteer to participate in this clinical trial and fully understand this study and sign the informed consent form (ICF), and willing to follow and capable of completing all testing procedures.
• Male or female aged 18-75 at the time of signing the ICF.
• Patients with histopathological confirmed primary colon adenocarcinoma
• MSS/RAS mutation patients with clinical stages T3N1-2 and T4N0-2
• an ECOG score of 0 or 1
• At least 1 measurable lesion according to RECIST 1.1 requirements.
• Patients must provide tumor tissue that meets the requirements for MSI/MMR testing.
• Expected survival period of at least 3 months.
• Negative hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (HBcAb) (-). If HBsAg (+) or HBcAb (+), hepatitis B virus deoxyribonucleic acid (HBV-DNA) must be <2500 copies/mL or 500 IU/mL before inclusion.
• Negative HCV antibody or HCV-RNA. If HCV-RNA is positive, the patient must have alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 × ULN to be included. Patients with co-infection of hepatitis B and hepatitis C should be excluded (HBsAg or HBcAb test is positive, and HCV antibody test is positive).
• Sufficient organ and bone marrow function confirmed by laboratory examinations within 7 days prior to the first use of the study medication, without severe hematopoietic abnormalities, heart, lung, liver, kidney dysfunction, and immune deficiency [no blood transfusion, albumin, recombinant human thrombopoietin, or colony stimulating factor (CSF) treatment was received within 14 days prior to the first use of the study

medication]:

1. Absolute value of neutrophils = 1.5 × 109/L, platelet = 100 × 109/L, hemoglobin concentration = 9g/dL);

2. Liver function test: bilirubin = 1.5 × ULN; aspartate transaminase and glutamate transaminase = 2.5 × ULN; if there is liver metastasis, AST and ALT = 5 × ULN;

3. Renal function test: serum creatinine = 1.5 × ULN, or creatinine clearance rate (CCr) = 60ml/min;

4. Coagulation: international standardized ratio (INR) = 1.5 × ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) = 1.5 × ULN;

5. Thyroid function: thyroid stimulating hormone (TSH) = ULN; Should there be abnormalities, the levels of FT3 and FT4 should be examined. If the levels of FT3 and FT4 are normal, the patients can be included;

• Women of childbearing age must undergo a serum pregnancy test within 14 days before treatment, and the result is negative. And they are willing to use medically recognized effective contraceptive methods (such as intrauterine devices, contraceptives, or condoms) during the study period and within 3 months after the last dose of the study medication. For male subjects with partners of childbearing age, surgical sterilization is required, or it is recommended to use effective contraceptive methods during the study period and within 3 months after the last dose of the study medication.

Exclusion Criteria:

• Patients with recurrent colon cancer, or primary colon cancer who has received the following treatments before: radiation therapy for tumors, surgery, chemotherapy, immunotherapy or molecular targeted therapy, and other clinical research drugs
• Severe infection (such as conditions which require intravenous infusion of antibiotics, antifungal drugs, or antiviral drugs) within 4 weeks prior to treatment, or unexplained fever >38.5 ? during screening/initial administration;
• Hypertension without effective control through proper antihypertensive medication treatment (systolic blood pressure = 140 mmHg or diastolic blood pressure = 90 mmHg);
• Obvious clinical bleeding symptoms or obvious bleeding tendencies (bleeding>30 mL within 3 months, vomiting blood, black stool, bloody stool), hemoptysis (fresh blood>5 mL within 4 weeks), etc. within the first 3 months of treatment. Or patients with conditions that require long-term anticoagulant therapy with warfarin or heparin or long-term antiplatelet therapy (aspirin = 300 mg/day or clopidogrel = 75 mg/day), such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep venous thrombosis, and pulmonary embolism.
• Active heart disease, including myocardial infarction and severe/unstable angina, occurred 6 months before treatment. Left ventricular ejection fraction<50% detected by echocardiography, with poor control of arrhythmia;
• Other malignant tumors within the past 5 years or at the same time (excluding cured skin basal cell carcinoma and cervical carcinoma in situ);
• Active or uncontrollable serious infections;
• Known human immunodeficiency virus (HIV) infection;
• Known clinically significant history of liver disease, including viral hepatitis [known carriers of hepatitis B virus (HBV) must exclude active HBV infection, i.e. HBV DNA positivity (>1 × 104 copies/mL or>2000 IU/ml);
• Known hepatitis C virus infection (HCV) and HCV RNA positivity (>1 × 103 copies/mL), or other hepatitis or cirrhosis;
• III-IV cardiac insufficiency according to the New York Heart Association (NYHA) standard or left ventricular ejection fraction (LVEF)<50% according to color Doppler ultrasound examination;
• Patients with active pulmonary tuberculosis.
• Patients with past and current conditions such as interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, and severely impaired lung function that may interfere with the detection and management of suspected drug-related pulmonary toxicity.
• The patient with known active or suspected autoimmune diseases. Patients with well controlled type I diabetes or immune related hypothyroidism who receive thyroid hormone replacement therapy are eligible. Patients with vitiligo who do not require intervention or with childhood asthma/allergies who have recovered without any intervention in adulthood are eligible.
• Patients who received live vaccine treatment within the first 28 days of enrollment.
• Patients who need to receive systemic corticosteroids (>10 mg/day prednisone efficacy dose) or other immunosuppressive drugs within the first 14 days of enrollment or during the study period.
• Any active infections that required systemic anti infective treatment, SARS-CoV-2 infection tested positive by RT-PCR within 14 days before the administration of the study drug. Subjects with a history of COVID-19 infection must have a negative RT-PCR test before the first administration of the study drug;
• History of major surgery within the first 28 days of randomization. The definition of major surgery in this study is that it requires at least 3 weeks of recovery time after surgery in order to receive surgery for treatment in this study.Patients who undergo tumor puncture or lymph node biopsy are eligible.
• Patient who has previously received treatment with other antibodies/drugs targeting immune checkpoints, such as PD-1, PD-L1, and cytotoxic T lymphocyte associated antigen 4 (CTLA-4).
• Patient who are currently participating in other clinical studies or planning to start treatment in this study less than 14 days from the end of the previous clinical study.
• Uncontrolled tumor related pain.
• History of severe allergies to any monoclonal antibody.
• History of allergies to any components of oxaliplatin and capecitabine.
• Women in pregnancy or lactating women.
• History of drug abuse of psychotropic substances or history of alcoholism.
• Any other disease with clinically significant metabolic abnormalities, physical examination abnormalities, or laboratory examination abnormalities, based on the judgment of the researcher, which is not suitable for the use of the study drug (such as having seizures and requiring treatment), or will affect the interpretation of the research results, or put the patient in a high-risk situation;
• Other factors that may cause the study to be terminated prematurely by the judgement of the researchers.

Related Conditions & MeSH terms

• Colon Cancer
• Colonic Neoplasms

Intervention

Drug:
• Serplulimab
Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
• Capecitabine
Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.
• Oxaliplatin
Participants will receive a pre-operative CAPEOX and a sequential CAPEOX plus Serplulimab regimen.

Locations

Country	Name	City	State
China	Ruijin Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Ruijin Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pathologic complete response	pCR	2 weeks after operation